drugset
Drugs / interleukin-6
last change Aug 2020 re-read 3 minutes ago

interleukin-6

Protein / enzyme biologic

Developed for
plasma cell myeloma
Investigated by
National Cancer Institute (NCI) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Trials 1

today NCT00470093 · Ph 0
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT00470093 Oct 2007 → Jan 2010 plasma cell myeloma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Terminated No outcome recorded Stop: Enrollment

Press releases naming this drug 5 releases

DateIssuerRelease
2020-08-04 Tiziana Life Sciences LTD Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients tizianalifesciences.com ↗
2020-06-29 Tiziana Life Sciences LTD Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19. tizianalifesciences.com ↗
2020-04-27 Tiziana Life Sciences LTD Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses tizianalifesciences.com ↗
2020-03-11 Tiziana Life Sciences LTD Tiziana Life Sciences plc To Expedite Development of its Fully Human Anti-Interleukin-6-Receptor Monoclonal Antibody, a Potential Treatment of Certain Patients Infected with Coronavirus COVID-19 tizianalifesciences.com ↗
2010-04-19 XOMA (US) LLC XOMA 052 Shows Potent In Vitro Inhibition of Interleukin-6 Production in Human Myeloma Cells xoma.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as interleukin-6 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00470093 ↗
Modality Protein / enzyme biologic “recombinant interleukin-6” NCT00470093 ↗
Route Subcutaneous “patients also receive recombinant interleukin-6 SC once daily.” NCT00470093 ↗